

REMARKS

Amendment to the title

The title has been amended to better reflect the subject matter of the application.

Pending claims

Claims 94-101, 103, 104 and 110 are pending. Claims 94, 98, 99, 102, 103, 104 and 110 are currently amended.

Nucleotide and/or Amino Acid Sequence Disclosure

The Examiner has indicated that the sequence listing does not comply with the requirements of 37 CFR 1.821 through 1.825 because “the stated total number of SEQ ID (stated as 254) . . . does not agree with the number of the last SEQ ID, which is 258.”

The previously submitted paper copy of the sequence listing contained a typographical error on the first page: it indicated that there were 254 sequences, when, in fact, there were 258 sequences (as contained in the computer readable copy form); four of the sequences were intentionally left blank.

With the present Amendment, Applicants have corrected the typographical error in the paper copy and have included herewith a substitute a PDF copy of the Sequence Listing and Applicants are also submitting by the USPTO’s Electronic Filing System (EFS) a substitute computer readable form (CFR) of the sequence listing.

Applicants believe that the corrected sequence listing complies with the requirements of 37 CFR 1.821 through 1.825.

Claim Rejections under 35 USC §112

The Examiner has rejected claims 94-101, 103, 104 and 110 under 35 USC §112, second paragraph, as being indefinite.

Claim 94. The Examiner indicates that there is uncertain antecedent basis for “The pharmaceutical composition” in line 1 because it appears to refer to a particular and specific pharmaceutical composition.

Claim 94, line 1, has been amended to read “A pharmaceutical composition”.

Claims 94, 98, 99, 101, 103, 104 and 110. The Examiner rejects these claims because they recite the limitation “an ApoA-I agonist” and that” there is uncertain antecedent bases for these limitations in the claims because it is unclear whether these ApoA-I agonists are the same as the ApoA-I agonist of claim 94, line 1”


Claim 94 has been amended to replace the word “an” with “the” to clarify that the ApoA-I agonist is the same as in line 1.

Claims 98, 99, 101, 103, 104 and 110 have been amended to clarify what is claimed.

It is respectfully submitted that the claims have been put in condition for allowance. Notification to this effect is earnestly solicited. The Examiner is encouraged to contact the Applicants' undersigned attorney to discuss this matter if any questions should arise upon further examination of the pending claims.

Respectfully submitted,

Date: March 5, 2007



Cynthia M. Bott, J.D., Ph.D.

Reg. No. 46,568

2800 Plymouth Road

Ann Arbor, MI 48105

Phone: 734-622-4476

Fax: 734-622-1553